BRIDGEWATER, N.J.--(BUSINESS WIRE)--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that the first patient has been enrolled in its clinical study of the HIF-1 alpha antagonist (EZN-2968). The open-label, non-randomized study is designed to evaluate the safety, tolerability, and pharmacokinetics of the HIF-1 alpha antagonist in 30 to 40 patients with advanced solid tumors or lymphoma.
